PT - JOURNAL ARTICLE AU - Casto, Amanda M. AU - Huang, Meei-Li AU - Nalla, Arun AU - Perchetti, Garrett AU - Sampoleo, Reigran AU - Shrestha, Lasata AU - Wei, Yulun AU - Zhu, Haiying AU - Greninger, Alexander L. AU - Jerome, Keith R. TI - Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and One Assay Kit AID - 10.1101/2020.03.13.20035618 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.13.20035618 4099 - http://medrxiv.org/content/early/2020/03/17/2020.03.13.20035618.short 4100 - http://medrxiv.org/content/early/2020/03/17/2020.03.13.20035618.full AB - More than 100,000 people worldwide are known to have been infected with SARS-CoV-2 beginning in December 2019. The virus has now spread to over 93 countries including the United States, with the largest cluster of US cases to date in the Seattle metropolitan area in Washington. Given the rapid increase in the number of local cases, the availability of accurate, high-throughput SARS-CoV-2 testing is vital to efforts to manage the current public health crisis. In the course of optimizing SARS-CoV-2 testing performed by the University of Washington Clinical Virology Lab (UW Virology Lab), we tested assays using seven different primer/probe sets and one assay kit. We found that the most sensitive assays were those the used the E-gene primer/probe set described by Corman et al. (Eurosurveillance 25(3), 2020, https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045) and the N2 set described by the CDC (Division of Viral Diseases, Centers for Disease Control and Prevention, 2020, https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-primer-probes.pdf). All assays tested were found to be highly specific for SARS-CoV-2, with no cross-reactivity with other respiratory viruses observed in our analyses regardless of the primer/probe set or kit used. These results will provide invaluable information to other clinical laboratories who are actively developing SARS-CoV-2 testing protocols at a time when increased testing capacity is urgently needed worldwide.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was support by the National Institute of Allergy and Infectious Diseases (NIAID) (grant number 5T32AI118690-04 T32 Training Grant to AMC at the Fred Hutchinson Cancer Research Center).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referred to in the manuscript has been included in the manuscript's tables.